Companies such as Medical Developments International and Corporate Travel Management have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider these financially stable, high-growth stocks. The list I’ve put together below are of stocks that compare favourably on all criteria, which potentially makes them a good investment if you believe the growth has not already been reflected in the share price.
Medical Developments International Limited (ASX:MVP)
Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment. The company now has 53 employees and with the company’s market capitalisation at AUD A$402.45M, we can put it in the small-cap group.
MVP’s projected future profit growth is an exceptional triple-digit, with an underlying triple-digit growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 55.07%. MVP’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. A potential addition to your portfolio? Take a look at its other fundamentals here.
Corporate Travel Management Limited (ASX:CTD)
Corporate Travel Management Limited, a travel management solutions company, manages the purchase and delivery of travel services for the corporate market worldwide. Established in 1994, and currently lead by Jamie Pherous, the company employs 2,200 people and has a market cap of AUD A$2.28B, putting it in the mid-cap category.
CTD’s forecasted bottom line growth is an exceptional 54.23%, driven by the underlying double-digit sales growth of 33.16% over the next few years. An affirming signal is when net income increase also comes with top-line growth. Even though some cost-reduction initiatives may have also pushed up margins, in the case of CTD, it does not appear extreme. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 21.03%. CTD’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Considering CTD as a potential investment? Take a look at its other fundamentals here.